UltraTech Cement Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 18, 2025, 7:01 pm

Competitors of UltraTech Cement Ltd

All Competitor Stocks of UltraTech Cement Ltd

Quarterly Result

Last Updated: August 1, 2025, 9:50 am

Below is a detailed analysis of the quarterly data for UltraTech Cement Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 21,275.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23,063.00 Cr. (Mar 2025) to 21,275.00 Cr., marking a decrease of 1,788.00 Cr..
• For Expenses, as of Jun 2025, the value is 16,869.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18,456.00 Cr. (Mar 2025) to 16,869.00 Cr., marking a decrease of 1,587.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 4,406.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,608.00 Cr. (Mar 2025) to 4,406.00 Cr., marking a decrease of 202.00 Cr..
• For OPM %, as of Jun 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 20.00% (Mar 2025) to 21.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 142.00 Cr.. The value appears strong and on an upward trend. It has increased from 93.00 Cr. (Mar 2025) to 142.00 Cr., marking an increase of 49.00 Cr..
• For Interest, as of Jun 2025, the value is 433.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 475.00 Cr. (Mar 2025) to 433.00 Cr., marking a decrease of 42.00 Cr..
• For Depreciation, as of Jun 2025, the value is 1,107.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,125.00 Cr. (Mar 2025) to 1,107.00 Cr., marking a decrease of 18.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 3,008.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,101.00 Cr. (Mar 2025) to 3,008.00 Cr., marking a decrease of 93.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Mar 2025) to 26.00%, marking an increase of 6.00%.
• For Net Profit, as of Jun 2025, the value is 2,221.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,475.00 Cr. (Mar 2025) to 2,221.00 Cr., marking a decrease of 254.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 75.54. The value appears to be declining and may need further review. It has decreased from 84.23 (Mar 2025) to 75.54, marking a decrease of 8.69.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:13 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: August 11, 2025, 3:02 pm

Below is a detailed analysis of the balance sheet data for UltraTech Cement Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 295.00 Cr.. The value appears strong and on an upward trend. It has increased from 289.00 Cr. (Mar 2024) to 295.00 Cr., marking an increase of 6.00 Cr..
• For Reserves, as of Mar 2025, the value is 70,412.00 Cr.. The value appears strong and on an upward trend. It has increased from 59,939.00 Cr. (Mar 2024) to 70,412.00 Cr., marking an increase of 10,473.00 Cr..
• For Borrowings, as of Mar 2025, the value is 24,102.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 11,403.00 Cr. (Mar 2024) to 24,102.00 Cr., marking an increase of 12,699.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 38,823.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29,167.00 Cr. (Mar 2024) to 38,823.00 Cr., marking an increase of 9,656.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 133,632.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100,797.00 Cr. (Mar 2024) to 133,632.00 Cr., marking an increase of 32,835.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 94,564.00 Cr.. The value appears strong and on an upward trend. It has increased from 62,878.00 Cr. (Mar 2024) to 94,564.00 Cr., marking an increase of 31,686.00 Cr..
• For CWIP, as of Mar 2025, the value is 6,234.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,811.00 Cr. (Mar 2024) to 6,234.00 Cr., marking a decrease of 577.00 Cr..
• For Investments, as of Mar 2025, the value is 5,156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,249.00 Cr. (Mar 2024) to 5,156.00 Cr., marking a decrease of 3,093.00 Cr..
• For Other Assets, as of Mar 2025, the value is 27,677.00 Cr.. The value appears strong and on an upward trend. It has increased from 22,859.00 Cr. (Mar 2024) to 27,677.00 Cr., marking an increase of 4,818.00 Cr..
• For Total Assets, as of Mar 2025, the value is 133,632.00 Cr.. The value appears strong and on an upward trend. It has increased from 100,797.00 Cr. (Mar 2024) to 133,632.00 Cr., marking an increase of 32,835.00 Cr..

Notably, the Reserves (70,412.00 Cr.) exceed the Borrowings (24,102.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for UltraTech Cement Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 205.30. This value is within the healthy range. It has decreased from 243.05 (Mar 24) to 205.30, marking a decrease of 37.75.
• For Diluted EPS (Rs.), as of Mar 25, the value is 205.13. This value is within the healthy range. It has decreased from 242.87 (Mar 24) to 205.13, marking a decrease of 37.74.
• For Cash EPS (Rs.), as of Mar 25, the value is 341.56. This value is within the healthy range. It has decreased from 350.80 (Mar 24) to 341.56, marking a decrease of 9.24.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 2,399.42. It has increased from 2,086.23 (Mar 24) to 2,399.42, marking an increase of 313.19.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 2,399.42. It has increased from 2,086.23 (Mar 24) to 2,399.42, marking an increase of 313.19.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2,577.55. It has increased from 2,456.20 (Mar 24) to 2,577.55, marking an increase of 121.35.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 451.39. This value is within the healthy range. It has decreased from 470.59 (Mar 24) to 451.39, marking a decrease of 19.20.
• For PBIT / Share (Rs.), as of Mar 25, the value is 315.14. This value is within the healthy range. It has decreased from 361.64 (Mar 24) to 315.14, marking a decrease of 46.50.
• For PBT / Share (Rs.), as of Mar 25, the value is 255.83. This value is within the healthy range. It has decreased from 325.62 (Mar 24) to 255.83, marking a decrease of 69.79.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 205.31. This value is within the healthy range. It has decreased from 241.85 (Mar 24) to 205.31, marking a decrease of 36.54.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 204.94. This value is within the healthy range. It has decreased from 242.65 (Mar 24) to 204.94, marking a decrease of 37.71.
• For PBDIT Margin (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 19.15 (Mar 24) to 17.51, marking a decrease of 1.64.
• For PBIT Margin (%), as of Mar 25, the value is 12.22. This value is within the healthy range. It has decreased from 14.72 (Mar 24) to 12.22, marking a decrease of 2.50.
• For PBT Margin (%), as of Mar 25, the value is 9.92. This value is below the healthy minimum of 10. It has decreased from 13.25 (Mar 24) to 9.92, marking a decrease of 3.33.
• For Net Profit Margin (%), as of Mar 25, the value is 7.96. This value is within the healthy range. It has decreased from 9.84 (Mar 24) to 7.96, marking a decrease of 1.88.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.95. This value is below the healthy minimum of 8. It has decreased from 9.87 (Mar 24) to 7.95, marking a decrease of 1.92.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.54. This value is below the healthy minimum of 15. It has decreased from 11.63 (Mar 24) to 8.54, marking a decrease of 3.09.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 10. It has decreased from 14.12 (Mar 24) to 9.16, marking a decrease of 4.96.
• For Return On Assets (%), as of Mar 25, the value is 4.51. This value is below the healthy minimum of 5. It has decreased from 6.94 (Mar 24) to 4.51, marking a decrease of 2.43.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.22. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.22, marking an increase of 0.14.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.32. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.32, marking an increase of 0.15.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has decreased from 0.73 (Mar 24) to 0.64, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1.5. It has decreased from 0.86 (Mar 24) to 0.73, marking a decrease of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.43, marking a decrease of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.49. This value exceeds the healthy maximum of 8. It has decreased from 9.49 (Mar 24) to 8.49, marking a decrease of 1.00.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 33.40. This value is within the healthy range. It has increased from 15.63 (Mar 24) to 33.40, marking an increase of 17.77.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.06. This value is within the healthy range. It has increased from 10.78 (Mar 24) to 20.06, marking an increase of 9.28.
• For Earning Retention Ratio (%), as of Mar 25, the value is 66.60. This value is within the healthy range. It has decreased from 84.37 (Mar 24) to 66.60, marking a decrease of 17.77.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.94. This value exceeds the healthy maximum of 70. It has decreased from 89.22 (Mar 24) to 79.94, marking a decrease of 9.28.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 8.06. This value is within the healthy range. It has decreased from 14.03 (Mar 24) to 8.06, marking a decrease of 5.97.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.72. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 4.72, marking a decrease of 3.57.
• For Enterprise Value (Cr.), as of Mar 25, the value is 363,558.87. It has increased from 290,900.97 (Mar 24) to 363,558.87, marking an increase of 72,657.90.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.79. This value exceeds the healthy maximum of 3. It has increased from 4.10 (Mar 24) to 4.79, marking an increase of 0.69.
• For EV / EBITDA (X), as of Mar 25, the value is 27.33. This value exceeds the healthy maximum of 15. It has increased from 21.41 (Mar 24) to 27.33, marking an increase of 5.92.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.97 (Mar 24) to 4.46, marking an increase of 0.49.
• For Retention Ratios (%), as of Mar 25, the value is 66.59. This value is within the healthy range. It has decreased from 84.36 (Mar 24) to 66.59, marking a decrease of 17.77.
• For Price / BV (X), as of Mar 25, the value is 4.79. This value exceeds the healthy maximum of 3. It has increased from 4.67 (Mar 24) to 4.79, marking an increase of 0.12.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.97 (Mar 24) to 4.46, marking an increase of 0.49.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness